Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
Open Access
- 20 November 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 21 (4), 1097-1103
- https://doi.org/10.1007/s00520-012-1630-5
Abstract
Tyrosine kinase inhibitors (TKIs) are now standard treatment for chronic myeloid leukemia (CML). While TKIs have less toxicity than previous treatments, they have side effects that can impact quality of life (QOL).Keywords
This publication has 20 references indexed in Scilit:
- Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemiaLeukemia & Lymphoma, 2011
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibJNCI Journal of the National Cancer Institute, 2011
- Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemiaCancer, 2010
- Identifying Clinically Meaningful Fatigue with the Fatigue Symptom InventoryJournal of Pain and Symptom Management, 2008
- Fatigue after treatment for early stage breast cancerCancer, 2007
- Psychometric evaluation of the Pittsburgh sleep quality index in cancer patientsJournal of Pain and Symptom Management, 2004
- Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS StudyJournal of Clinical Oncology, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- The Italian SF-36 Health SurveyJournal of Clinical Epidemiology, 1998
- The CES-D ScaleApplied Psychological Measurement, 1977